Pierre Y. Cremieux
Education
Ph.D. and M.A., economics, University of California, Berkeley; B.A., economics, University of Maryland
Summary of Experience
Pierre Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the US and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.
Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor-related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years.
His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and the American Journal of Managed Care. Dr. Cremieux's research has been cited in leading media outlets including The Wall Street Journal and Forbes.
Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and Yale's School of Management.
Prior to joining Analysis Group in 1997, Dr. Cremieux spent five years as a professor at the University du Québec à Montréal, and served as an adjunct professor from 1997 to 2018.
Provided Expert Testimony
- Bone Care International v. Roxane Labs, et al.
- ERISA Class Action against Provider of Retirement Plan Services to Small- and Mid-Sized Plans
- Pharmacyclics LLC, et al. v. Fresenius Kabi USA LLC, et al.
- US v. DaVita Inc. and Kent Thiry
- Wellbutrin XL Antitrust Litigation
Additional Cases
- Analysis Group Pro Bono Team Assists Harvard Medical School in TB Genome Machine Learning Project
- Analysis Group Team Joins Partners In Health for Pro Bono Data Analysis in Lesotho
- Analysis in NFL Players Association Deflategate Matter
- Analysis of ROI for Bariatric Surgery
- Assessing Adverse Events
- Assessing Health Care Patent Infringement Claims
- Boston Symphony Orchestra Compensation Analysis
- Bracco Diagnostics, Inc. v. Amersham Health, Inc.
- Confidential Ongoing Pharmaceutical Mass Tort Matter
- Economic Impact of Rwandan Hospital on Its Community Is Examined Pro Bono by Analysis Group at Request of PIH
- EMC Corp. v. Karwowska
- GlaxoSmithKline Holdings (Americas) Inc. v. Commissioner of the IRS
- High-Tech Employee Class Action Involving Alleged No-Poaching Agreements
- In re: TFT-LCD (Flat Panel) Antitrust Litigation
- Louisiana Wholesale Drug Co., Inc. v. Sanofi-Aventis
- Multiple Antitrust Litigations on Behalf of Large Semiconductor Manufacturer
- OCC administrative actions against Rohan Ramchandani, former head of European FX Spot Trading at Citibank, and Richard Usher, former head of EMEA FX Spot Trading at JPMorgan Chase
- Pat Cason-Merenda et al v Detroit Medical Center et al
- Toyota Industries and Cascade Corporation Transaction
- United States v. Richard Usher, et al.
- Vitamins Antitrust Litigation
-
The Economic Impact of Immigration on the United States
White Paper, 2024
2024Arcelus A, Chiapa C, Cremieux P, Garibotti M, Hearey O, Hyun Y, Jinks L, Lehmann JY, Lu Y, Narula K, Palacios L, Zhang H
-
Same-Day Testing with Initiation of Antiretroviral Therapy or Tuberculosis Treatment Versus Standard Care for Persons Presenting with Tuberculosis Symptoms at HIV Diagnosis: A Randomized Open-Label Trial from Haiti
PLOS, 2023
2023Dorvil N, Rivera VR, Riviere C, Berman B, Severe P, Bang H, Lavoile K, Devieux JG, Faustin M, Saintyl G, Mendicuti MD, Pierre S, Apollon A, Dumond E, Forestal GPL, Rouzier V, Marcelin A, McNairy ML, Walsh KF, Dupnik K, Reif LK, Byrne AL, Bousleiman S, Orvis E, Joseph P, Cremieux PY, Pape JW, Koenig SP
-
Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification among Patients with Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-Income Countries
MedRxiv, 2023
2023Dupnik K, Rivera VR, Dorvil N, Akbarnejad H, Gao Y, Liu J, Apollon A, Dumond E, Riviere C, Severe P, Lavoile K, Mendicuti MAD, Pierre S, Rouzier V, Walsh KF, Byrne AL, Joseph P, Cremieux PY, Pape JW, Koenig SP
-
A Commissioners’ History of Cartel Enforcement in Europe: Multidimensional Comparison of Administrations
Journal of European Competition Law & Practice, 2020
2020 -
Diagnostic Yield of Active Case Finding for Tuberculosis at Human Immunodeficiency Virus Testing in Haiti
The International Journal of Tuberculosis and Lung Disease, 2019
2019Rivera VR, Lu L, Ocheretina O, Jean Juste MA, Julma P, Archange D, Moise CG, Homeus F, Phanor PD, Petión S, Cremieux PY, Fitzgerald DW, Pape JW, Koenig SP
-
Improved Outcomes with High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment in Haiti
Clinical Infectious Diseases, 2019
2019Walsh KF, Vilbrun SC, Souroutzidis A, Delva S, Joissaint G, Mathurin L, Ocheretina O, Cremieux P, Pape JW, Koenig SP
-
Fiscal state aid: are US companies being unfairly targeted?
Global Competition Review, January 5, 2018
2018Cremieux P, Van Audenrode M, Mishol D
-
Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial
PLoS Medicine. July 2017;14 (7) (no pagination)(e1002357)
2017Koenig SP, Dorvil N, Dévieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, Lavoile K, Perodin C, Apollon A, Duverger L, McNairy ML, Hennessey KA, Souroutzidis A, Cremieux PY, Severe P, Pape JW
-
Diagnostic yield of active case finding for tuberculosis and HIV at the household level in slums in Haiti
International Journal of Tuberculosis and Lung Disease. 01 Nov 2017;21(11):1140-1146+i
2017Rivera VR, Jean-Juste MA, Gluck SC, Reeder HT, Sainristil J, Julma P, Peck M, Joseph P, Ocheretina O, Perodin C, Secours R, Duran-Mendicuti M, Hashiguchi L, Cremieux PY, Koenig SP, Pape JW
-
Retention in Care among Patients with Early HIV Disease in Haiti
Journal of the International Association of Providers of AIDS Care. 01 Nov 2017;16(6):523-526
2017Hennessey KA, Leger TD, Rivera VR, Marcelin A, McNairy ML, Guiteau C, Devieux JG, Marcelin Y, Charles B, Cremieux PY, Koenig SP, Pape JW
-
A Comparison of Damage Theories in Price-Fixing Cases in the United States, Canada, and the European Union
American Bar Association Section of Litigation, The Class Actions and Derivative Suits Newsletter, Winter 2017
2017 -
Calculating Damages in Price-Fixing Cases in the United States, Canada, and the European Union
American Bar Association Section of Litigation, The Class Actions and Derivative Suits Newsletter, Spring 2017
2017 -
Use and Abuse: The Myth of Divided Antitrust Economics
Concurrences, March 2016
2016 -
Can social media data lead to earlier detection of drug-related adverse events
Pharmacoepidemiology and Drug Safety, 2016 Sep 7 doi: 10.1002/pds.4090. [Epub ahead of print]
2016Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P.
-
Enforcement of Anticollusion Laws against Domestic and Foreign Firms
Journal of Law and Economics, Volume 59, Number 4, November 2016
2016 -
Antitrust Private Damages Actions in the United States, Canada and the European Union
Competition Policy International: Antitrust Chronicle, Spring 2016, Volume 3, Number 1
2016 -
Average overcharge models and determining individual harm in collective actions
Concurrences N° 2-2015, pp. 38-44
2015 -
What Attorneys Should Know About FDA’s MedWatch Data
Law360, January 29, 2014
2014 -
Applying Econometrics to Address Class Certification
Econometrics: Legal, Practical, and Technical Issues (Second Edition)
2014Cremieiux P, Decter A, Levin C, McFarland H, Nelson P, Rothman D, Smith D
-
Superior Outcomes and Lower Outpatient Costs with Scale-up of Antiretroviral Therapy at the Gheskio Clinic in Port-Au-Prince, Haiti
Journal of Acquired Immune Deficiency Syndromes, 2014
2014Riviere C, Faust E, Miller T, Beck EJ, Baruwa E, Severe P, Severe K, Riché CT, Cassagnol R, Atwood S, Esperance M, Webster L, Cremieux P, Pape JW, Koenig SP
-
Brief of Antitrust Economists as Amici Curiae in Support of Respondents
Amicus Curiae Brief on Reverse Payment Settlements, February 28, 2013
2013Cockburn I, Cremieux P, Grabowski H, Greenberg P, Hubbard R, Hughes J, Snyder E, Stangle B
-
Book Review: Monopsony in Law and Economics
Journal of Economic Literature, Vol. 49, No. 4
2011 -
Assessing the Relationship Between Compliance with Antidepressant Therapy and Employer Costs Among Employees in the United States
Journal of Occupational and Environmental Medicine; 52(2) : 115-124. 2010
2010Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux P, Greenberg P
-
Proof of Common Impact in Antitrust Litigation: The Value of Regression Analysis
George Mason Law Review
2010Cremieux P, Simmons I, Snyder E
-
The Role of Experts in Antitrust Class Certification
Antitrust Class Action Handbook (The American Bar Association, 2010)
2010 -
The Economic Impact of the Clinical Benefits of Bariatric Surgery in Diabetes Patients with BMI is Great than Equal 35 kg per m2
Obesity (Silver Spring). 2010 Sep 9
2010Klein S, Ghosh A, Cremieux P, Eapen S, McGavock T
-
The impact of bariatric surgery on comorbidities and medication use among obese patients
Obesity Surgery; 20 (7): 861-870. 2010
2010Cremieux P, Ledoux S, Clerici C, Cremieux F, Buessing M
-
Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa
Ann Pharmacother. 2010;44(3):595; author reply 595-6.
2010Lefebvre P, Vekeman F, Cremieux P
-
Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs
Curr Med Res Opin. 2009 Apr;25(4):869-77
2009Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D
-
The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence
Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. Review
2009Duh M, Cahill K, Paradis P, Cremieux P, Greenberg P
-
Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 × 2 tables
Biostatistics, April 2009, 10(2): 275-281
2009Tian L, Cai T, Pfeffer M, Piankov N, Cremieux P, Wei LJ
-
A Study on the Economic Impact of Bariatric Surgery
American Journal of Managed Care, 2008 Sep;14(9):589-96.
2008Cremieux P, Buchwald H, Sikora S, Ghosh A, Yang H, Buessing M
-
Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators
Bariatric Times, November 2008
2008Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M
-
The Value Of Antihypertensive Drugs: A Perspective On Medical Innovation
Health Affairs
2007Cutler D, Long G, Berndt E, Royer J, Fournier A, Sasser A, Cremieux P
-
Pharmaceutical Spending and Health Outcomes
Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective
2007Cremieux P, Jarvinen D, Long G, Merrigan P
-
Tips From the Experts: Getting the Most Out of Your Experts
Expert Alert Newsletter of the Section of Litigation's Committee on Experts, American Bar Association
2007Cremieux P, Eccher E, Herscovici S
-
The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine
Disease Management
2007Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux P
-
Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease
Curr Med Res Opin 2007 Jul;23(7):1571-4
2007Einarson T, Machado M, Walker J, Iskedjian M, Cremieux P, Van Audenrode M, Lefebvre P
-
Do drugs reduce utilisation of other healthcare resources?
Pharmacoeconomics 2007;25(3):209-21
2007Cremieux P, Ouellette P, Petit P
-
The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS)
Healthc Q 2007;10(2):38-46
2007Cremieux P, Fortin P, Meilleur M, Montague T, Royer J
-
Relationship Between Hemoglobin Level and Quality of Life in Anemic Patients With Chronic Kidney Disease Receiving Epoetin Alfa
Curr Med Res Opin. 2006; 22(10):1929-1937
2006Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux P
-
The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease
Curr Med Res Opin 2006 Dec;22(12):2329-36
2006 -
Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application
J Oncol Pharm Pract. 2006; 12(3):165-178
2006Cremieux P, Vekeman F, Lefebvre P
-
Assessing Conflict, Impact, and Common Methods of Proof in Intermediate Indirect-Purchaser Class Action Litigation
Newsletter of the Economics Committee of the ABA's Antitrust Section
2006Cremieux P, Herscovici S, Decter A
-
The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke, and Myocardial Infarction in the United States
National Bureau of Economic Research Working Paper
2006Berndt E, Sasser A, Long G, Cremieux P, Royer J, Fournier AA
-
Hospital Cost Flexibility in the Presence of Many Outputs: A Public-Private Comparison
Health Care Manag Sci. 2005 May;8(2):111-20
2005Cremieux P, Ouellette P, Rimbaud F, Vigeant S
-
Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis
Clin Drug Investig. 2005;25(1):33-48.
2005Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT
-
Public and Private Pharmaceutical Spending As Determinants of Health Outcomes in Canada
Health Econ. 2005 Feb;14(2):107-16.
2005Cremieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K
-
Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
J Manag Care Pharm. 2004 Nov-Dec;10(6):531-7
2004Cremieux P, Fastenau J, Kosicki G, Piech C, Fendrick A
-
Incidence and Costs of Accidents among Attention-Deficit, Hyperactivity Disorder Patients
J Adolesc Health. 2004 Oct;35(4):346.e1-9.
2004Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.
-
Measuring Hospital Efficiency in the Presence of Quasi-Fixed Inputs: An Analysis of Québec Hospitals
Journal of Productivity Analysis 2004;21(2):183-99
2004Bilodeau D, Cremieux P, Jaumard B, Ouellette P, Vovor T
-
Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis
Pharmacotherapy. 2003 May;23(5):690-3; discussion 693-4.
2003 -
Cost Effectiveness of rHuEPO in Oncology
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer. M.R. Nowrousian (Ed.), SpringerWien New York, 2002
2002Cremieux P, Dial E, Gustafson M, Sarokhan B, Slavin M
-
Anemia-Related Costs for Cancer Patients
Managed Care Med 2002;6(1):20-8
2002Barnett A, Cremieux P, Fendrick A, George M, Slavin M
-
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
Cancer 2002 Aug 15;95(4):888-95
2002Crawford J1, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.
-
Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy
J Clin Oncol. 2002 Jun 1;20(11):2757-8.
2002Gabrilove JL, Sarokhan B, Cremieux P
-
The costs of cancer: cancer-related conditions can add dramatically to overall costs of care
J Managed Care Med 2002;6(1):12-9
2002Cremieux P, Slavin M, Fendrick A, Hiriak T, Kosicki G
-
Hospital technology in a non-market health care system
Southern Economic Journal 2002;68(3):511-29
2002Bilodeau D, Cremieux P, Ouellette P
-
L'évolution du régime d'assurance-médicament (Changes in the Drug Prescription Coverage in Quebec)
Annuaire du Quebec 2002; Editions Fides
2002Bluteau JP, Cremieux P, Ouellete P
-
Pharmaceutical Spending and Health Outcomes in the United States
Investing in Health: The Social and Economic Benefits of Healthcare Innovation 2001; 14: 59-76
2001Cremieux P, Ouellette P, Meilleur M, Leong S, Greenberg P, Birnbaum H
-
Omitted Variable Bias and Hospital Costs
J Health Econ 2001 Mar;20(2):271-82
2001Cremieux P, Ouellette P
-
Actual and perceived impacts of tobacco regulation on restaurants and firms
Tob Control 2001 Mar;10(1):33-7
2001Cremieux P, Ouellette P
-
L’évaluation de l’efficience budgétaire des CLSC au Québec à partir de la méthode DEA
L’Actualité Economique 2001;77(3):409-24
2001Cremieux P, Gadbois D, Jaumard B, Ouellette P, Vovor T
-
The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis
Am J Manag Care 2000 Nov;6(11):1243-51
2000Barnett A, Birnbaum H, Cremieux P, Fendrick A, Slavin M
-
Cost of Outpatient Blood Transfusion in Cancer Patients
J Clin Oncol 2000 Jul;18(14):2755-61
2000Cremieux P, Barrett B, Anderson K, Slavin M
-
Costs Associated with Anemia and Cancer
ONE: Oncology Economics 2000;1(11):1-7
2000Cremieux P, Gubens M, Holland M, Slavin M
-
Management of Major Depression in the Workplace: Impact on Employee Work Loss
Disease Management & Health Outcomes 2000;7(3):163-71
2000 -
Hospital Cost Function in a Non-Market Health Care System
Review of Economics and Statistics 2000;82(3):1-11
2000Bilodeau D, Cremieux P, Ouellette P
-
Using healthcare claims data for outcomes research and pharmacoeconomic analyses
Pharmacoeconomics 1999 Jul;16(1):1-8
1999Birnbaum H, Cremieux P, Greenberg P, LeLorier J, Ostrander J, Venditti L
-
Health care spending as determinants of health outcomes
Health Econ 1999 Nov;8(7):627-39
1999Cremieux P, Ouellette P, Pilon C
-
Pharmacoeconomics and health policy: Current applications and prospects for the future
Pharmacoeconomics 1999 Nov;16(5 Pt 1):425-32
1999Greenberg P, Arcelus A, Birnbaum H, Cremieux P, LeLorier J, Ouellette P, Slavin M
-
Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anemia
Pharmacoeconomics 1999 Nov;16(5 Pt 1):459-72
1999Cremieux P, Finkelstein S, Berndt E, Crawford J, Slavin M
-
La Performance des CLSC au Quebec, (Local Health Clinic Performance in Quebec)
L'Actualité Economique 1998;74(2):157-81
1998Cremieux P, Ouellette P, Gadbois D
-
Une analyse du contexte budgétaire de l’activité médicale au Québec (An Analysis of the Budgetary Context of Medical Activity in Québec)
Le Médecin du Québec 1997 Aug
1997Cremieux P, Ouellette P
-
Etude d’Impact du Projet de Loi sur le Tabac (Impact Report on the Proposed Tobacco Law)
Ministry of Health and Social Services 1997
1997Cremieux P, Fortin P, Lavoie F, Ouellette P, St Pierre Y
-
Is The U.S./Canada Unemployment Gap Truly Large? A Labor Flow Analysis
The Flow Approach to Labor Market Analysis
1996 -
Mergers and Bargaining in the US Airline Industry
Review of Labour Economics and Industrial Relations
1996 -
Why Strike Insurance Is Unilateral: Evidence From the Airline Industry's Mutual Aid Pact
Journal of Labor Research
1996 -
The Effect of Deregulation on Employee Earnings: Pilots, Flight Attendants, and Mechanics, 1959-1992
Industrial and Labor Relations Review
1996 -
The Impact of Unemployment Insurance on Job-Search Productivity, the Reservation Wage, the Probability of Re-Employment, and the Post-Displacement Wage
Insurance Program Evaluation Report
1995Cremieux P, Fortin P, Storer P, Van Audenrode M
-
June 27, 2022
-
August 26, 2024
-
January 19, 2024
-
March 21, 2023
-
January 18, 2023
-
August 30, 2022
-
April 21, 2022
-
August 16, 2021
-
May 20, 2021
-
February 2, 2021